Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors

1 Nov 2003

Abstract excerpt

The presence of various levels of anti-adenovirus serotype 5 (Ad5)-neutralizing antibodies in humans is thought to contribute to the inconsistent clinical results obtained so far in diverse gene transfer and vaccination studies and might preclude universal dosing with recombinant Ad5. Prescreening of individuals eligible for Ad5 or alternative serotype treatment and subsequently tailoring the vector dose might...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Herpesvirus Infections and Treatments
Share to Viral gastroenteritis research and epidemiology
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 14605137
DOI: 10.1128/jcm.41.11.5046-5052.2003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy VectorsPMID 14605137Read ↗

Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectorsSemantic proximity Read ↗

Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon ProteinSemantic proximity Read ↗

Clinical enrollment assay to detect preexisting neutralizing antibodies to AAV6 with demonstrated transgene expression in gene therapy trialsSemantic proximity Read ↗

Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5–based ConstructsSemantic proximity Read ↗

Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapiesSemantic proximity Read ↗

Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple SpeciesSemantic proximity Read ↗

Vaccination with Ad5 vectors expands Ad5-specific CD8 T cells without altering memory phenotype or functionality.Semantic proximity Read ↗

Lateral Flow Immunochromatographic Assay for Adenovirus Antibody Detection in Human Serum Using Gold Nanoparticles and Quantum DotsSemantic proximity Read ↗

Adenoviruses as gene/vaccine delivery vectors: promises and pitfallsSemantic proximity Read ↗

Preexisting antibody assays for gene therapy: Considerations on patient selection cutoffs and companion diagnostic requirementsSemantic proximity Read ↗

Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapySemantic proximity Read ↗

Rapid Detection of AAV8 Binding Antibodies in Gene Therapy Candidates: Development of a Point-of-Care ApproachSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.